王宝亮;郭亚萌;关运祥;王鑫鑫;

• 1:河南中医药大学第一附属医院
• 2:河南中医药大学

摘要(Abstract)：

目的通过网络药理学探讨黄芪、附子治疗重症肌无力(myasthenia gravis,MG)的药理机制,为益气温阳法的临床应用提供理论依据。方法总结归纳出用益气温阳法治疗MG患者的主要中医临床症状,利用TCMSP、Swiss Target Prediction预测和筛选黄芪、附子的活性成分与作用靶点,用Gene Cards分别收集症状和MG疾病相关靶点,并在Venny 2.1. 0获取共同靶点,通过R语言进行GO和KEGG富集分析,预测其作用机制。结果筛选出38个化学成分和796个靶点,83个共同靶点,包括AKT1、IL6、TNF、VEGFA、TP53、JUN、MAPK1等。黄芪、附子治疗重症肌无力机制可能涉及病毒感染通路、免疫相关通路、PI3K-Akt信号通路等。结论黄芪、附子治疗MG的药理机制是通过多组分、多靶点、多通路实现的,用益气温阳法治疗MG有一定的临床价值。

关键词(KeyWords)： 益气温阳法;黄芪;附子;网络药理学;重症肌无力

Abstract:

Keywords:

基金项目(Foundation): 国家中医药管理局第六批全国老中医药专家学术继承项目（国中医药人教发[2017]9）;; 河南省中医药科学研究专项（TCM2019010）

作者(Authors): 王宝亮;郭亚萌;关运祥;王鑫鑫;

DOI: 10.13729/j.issn.1671-7813.Z20201001

参考文献(References)：

• [1]李柱一．中国重症肌无力诊断和治疗指南2015[J]．中华神经科杂志，2015,48(11):934-940.
• [2] GILHUS NE,NACU A,ANDERSEN JB,et al. Myasthenia gravis andrisks for comorbidity[J]. European Journal of Neurology,2015,22(1):17-23.
• [3]盛昭园，陈钢，董云，等．李庚和重症肌无力诊治经验[J]．辽宁中医杂志，2013,40(6):1084-1085.
• [4]陈国辉，黄文凤．黄芪的化学成分及药理作用研究进展[J]．中国新药杂志，2008(17):1482-1485.
• [5]王杰，张怀亮．重用黄芪治疗重症肌无力验案[J]．山东中医杂志，2014,33(3):236-237.
• [6]牛广华，孙旭，张春明，等．黄芪复方对重症肌无力患者淋巴细胞亚群、免疫球蛋白及补体的影响[J]．中国中西医结合杂志，2009,29(4):305-308.
• [7]季苗苗．黄芪对附子的吸收影响及其影响机理的研究[D]．南昌：江西中医药大学，2019.
• [8]李少红．益气温阳法治疗重症肌无力临床疗效评价[D]．北京：北京中医药大学，2019.
• [9]黄子天，邱仕君．益气升阳、强肌健力治疗重症肌无力[J]．中医杂志，2020,61(7):632-634.
• [10]盛昭园，陈钢，董云，等．李庚和重症肌无力诊治经验[J]．辽宁中医杂志，2013,40(6):1084-1085.
• [11]高斌．王宝亮教授诊治重症肌无力辨证遣药经验[J]．中医研究，2012,25(11):56-58.
• [12]都立澜，朱剑飞．临床中医英语[M]．青岛：中国海洋大学出版社，2018.
• [13]张雨，李恒，李克宁，等．复方中药网络药理学的研究进展[J]．中成药，2018,40(7):1584-1588.
• [14]孙涓，余世春．槲皮素的研究进展[J]．现代中药研究与实践，2011,25(3):85-88.
• [15] DEVI K P,MALAR D S,NABAVI S F,et al. Kaempferol and in-flammation:From chemistry to medicine[J]. Pharmacological Re-search,2015(99):1-10.
• [16] GONG G,GUAN Y Y,ZHANG Z L,et al. Isorhamnetin:A reviewof pharmacological effects[J]. Biomedicine&Pharmacotherapy,2020(128):110301.
• [17]陈伟明，熊旭明．异鼠李素对LPS诱导下THP-1细胞炎症因子释放的影响[J]．广州医药，2017,48(5):9-13.
• [18] GAO JQ,LIU ZJ,CHEN T,et al. Pharmaceutical properties of caly-cosin,the major bioactive isoflavonoid in the dry root extract of Ra-dix astragali[J]. Pharmaceutical biology,2014,52(9):1217-1222.
• [19] WANG CC,CHEN LG,YANG LL. Inducible nitric oxide synthaseinhibitor of the Chinese herb I. Saposhnikovia divaricata(Turcz.)Schischk[J]. Cancer letters,1999,145(1-2):151-157.
• [20] WEBER US, STEFFEN B, SIEGERS CP. Antitumor-activities ofcoumarin, 7-hydroxy-coumarin and its glucuronide in severalhuman tumor cell lines[J]. Research communications in molecularpathology and pharmacology,1998,99(2):193-206.
• [21] CHENG ZHUOAN,QIU SHAOBO,JIANG LIN,et al. MiR-320ais downregulated in patients with myasthenia gravis and modulatesinflammatory cytokines production by targeting mitogen-activatedprotein kinase 1[J]. Journal of clinical immunology,2013, 33(3):567-576.
• [22] DENG C,GOLUSZKO E,TUZUN,et al. Resistance to experimen-tal autoimmune myasthenia gravis in IL-6-deficient mice is asso-ciated with reduced germinal center formation and C3 production[J]. The Journal of Immunology,2002,169(2):1077-1083.
• [23] UTSUGISAWA K,NAGANE Y,OBARA D,et al. Interleukin-2production by peripheral blood mononuclear cells from patients withmyasthenia gravis[J]. European neurology,2003,49(3):160-163.
• [24] ULUSOY C,KIM E, TüZüN E, et al. Preferential production ofIgG1, IL-4 and IL-10 in MuSK-immunized mice[J]. ClinicalImmunology,2014,151(2):155-163.
• [25] SASSANO P,PAPARO F,RAMIERI V,et al. Interleukine-6(IL-6)may be a link between myasthenia gravis and myoepitheliomaof the parotid gland[J]. Medical hypotheses,2007,68(2):314-317.
• [26] CIMPEAN AM, RAICA M, ENCICA S, et al. Immunohistochemi-cal expression of vascular endothelial growth factor A(VEGF),and its receptors(VEGFR1, 2)in normal and pathologic condi-tions of the human thymus.[J]. Annals of Anatomy-anatomischerAnzeiger,2008,190(3):238-245.
• [27] UZAWA A, KAWAGUCHI N, HIMURO K, et al. Serum cytokineand chemokine profiles in patients with myasthenia gravis[J].Clinical and Experimental Immunology,2014,176(2):232-237.
• [28]刘荣雕，阮灵伟．PI3K-Akt信号通路与病毒感染[J]．生物技术通报，2013(6):53-62.
• [29] Cavalcante P, Galbardi B, Franzi S, et al. Increased expression ofToll-like receptors 7 and 9 in myasthenia gravis thymus character-ized by active Epstein–Barr virus infection[J]. Immunobiology,2016, 221(4):516-527.
• [30] ZOU J, PRESKY DH, WU CY, et al. Differential associations be-tween the cytoplasmic regions of the interleukin-12 receptor sub-unitsβ1 andβ2 and JAK kinases[J]. Journal of Biological Chem-istry,1997,272(9):6073-6077.
• [31] WEAVER CT, HATTON RD, MANGAN PR, et al. IL-17 fami-ly cytokines and the expanding diversity of effector T cell lineages[J]. Annu. Rev. Immunol,2007(25):821-852.
• [32]林婧．重症肌无力危象患者血清IL-17水平及其临床意义研究[D]．武汉：华中科技大学，2013.